A randomised study of continuous infusional 5-fluorouracil with or without bolus mitomycin-C in patients with advanced colorectal cancer

ISRCTN ISRCTN27478455
DOI https://doi.org/10.1186/ISRCTN27478455
Secondary identifying numbers COMBAT COIRE
Submission date
19/08/2002
Registration date
19/08/2002
Last edited
30/05/2012
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study information

Study designMulticentre randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study objectivesNot provided at time of registration
Ethics approval(s)No ethics approval information required at time of registration.
Health condition(s) or problem(s) studiedColon, Rectal cancer
Intervention1. Regimen one: continuous infusion 5-fluorouracil. The infusion will be given for 12 weeks and for a further 12 weeks in responding patients or patients with stable disease.
2. Regimen two: continuous infusion 5-fluorouracil given as above plus mitomycin-C given every 6 weeks for two courses and to a total of four courses in responding patients or patients with stable disease.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)5-fluorouracil, mitomycin-C
Primary outcome measureAdded 05/08/09:
1. tumour response
2. survival
3. toxicity
4. quality of life (QoL)
Secondary outcome measuresNot provided at time of registration
Overall study start date13/03/1995
Completion date13/03/1996

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants200 (final: 98 active, 97 controls)
Key inclusion criteria1. Histological evidence of metastatic adenocarcinoma of the colon or rectum not amenable to surgery or radiotherapy
2. Patients evaluable for response must have bi-dimensionally measurable disease
3. Patients with no measurable disease
4. Adequate bone marrow function
5. Serum creatinine within normal range
6. Life expectancy of greater than 3 months
7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Key exclusion criteria1. History of other malignant disease other than non melanotic skin cancer or carcinoma in situ of the cervix
2. Prior treatment with any cytotoxic agent except adjuvant chemotherapy completed more than 12 months from randomisation
3. Intracerebral metastases or meningeal carcinomatosis
4. Medical contraindications to treatment
Date of first enrolment13/03/1995
Date of final enrolment13/03/1996

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

The Royal Marsden NHS Foundation Trust (UK)
Hospital/treatment centre

Downs Road
Sutton
SM2 5PT
England
United Kingdom

ROR logo "ROR" https://ror.org/0008wzh48

Funders

Funder type

Hospital/treatment centre

The Royal Marsden NHS Foundation Trust (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/10/1997 Yes No